These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 38842630)

  • 1. Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients.
    Konuma T; Hamatani-Asakura M; Nagai E; Adachi E; Kato S; Isobe M; Monna-Oiwa M; Takahashi S; Yotsuyanagi H; Nannya Y
    Int J Hematol; 2024 Aug; 120(2):229-240. PubMed ID: 38842630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    Clin Infect Dis; 2024 Aug; 79(2):542-554. PubMed ID: 38801746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Wagenhäuser I; Almanzar G; Förg FB; Stein A; Eiter I; Reusch J; Mees J; Herzog A; Vogel U; Frey A; Lâm TT; Schubert-Unkmeir A; Dölken L; Kurzai O; Frantz S; Gabel A; Petri N; Prelog M; Krone M
    Vaccine; 2024 Aug; 42(21):126132. PubMed ID: 39034219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
    Liu S; van Dijk LLA; den Hartog Y; Hoek R; Verschuuren E; Geurtsvankessel CH; de Vries RD; Van Baarle D; Buter CVL
    Vaccine; 2024 Oct; 42(24):126250. PubMed ID: 39226789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 cellular and humoral responses in vaccine-naive individuals during the first two waves of COVID-19 infections in the southern region of The Netherlands: a cross-sectional population-based study.
    Hanssen DAT; Arts K; Nix WHV; Sweelssen NNB; Welbers TTJ; de Theije C; Wieten L; Pagen DME; Brinkhues S; Penders J; Dukers-Muijrers NHTM; Hoebe CJPA; Savelkoul PHM; van Loo IHM
    Microbiol Spectr; 2024 Jun; 12(6):e0012624. PubMed ID: 38686954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen-specific T helper cells and cytokine profiles predict intensity and longevity of cellular and humoral responses to SARS-CoV-2 booster vaccination.
    Page L; Dennehy K; Mueller K; Girl P; Loell E; Buijze H; Classen JM; Messmann H; Roemmele C; Hoffmann R; Wurster S; Fuchs A
    Front Immunol; 2024; 15():1423766. PubMed ID: 39267758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents.
    Torres I; Albert E; Giménez E; Alcaraz MJ; Botija P; Amat P; Remigia MJ; Beltrán MJ; Rodado C; Huntley D; Olea B; Navarro D
    Clin Microbiol Infect; 2021 Nov; 27(11):1672-1677. PubMed ID: 34174397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiparametric analysis of the specific immune response against SARS-CoV-2.
    Vránová L; Poláková I; Vaníková Š; Saláková M; Musil J; Vaníčková M; Vencálek O; Holub M; Bohoněk M; Řezáč D; Dresler J; Tachezy R; Šmahel M
    Infect Dis (Lond); 2024 Oct; 56(10):851-869. PubMed ID: 38805304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
    Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
    EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.
    Byrne J; Gu L; Garcia-Leon A; Gaillard CM; Saini G; Alalwan D; Tomás-Cortázar J; Kenny G; Donohue S; Reynolds B; O'Gorman T; Landay A; Doran P; Stemler J; Koehler P; Cox RJ; Olesen OF; Lelievre JD; O'Broin C; Savinelli S; Feeney ER; O'Halloran JA; Cotter A; Horgan M; Kelly C; Sadlier C; de Barra E; Cornely OA; Gautier V; Mallon PW
    Front Immunol; 2024; 15():1445653. PubMed ID: 39355249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
    Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
    J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
    Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study.
    Novak F; Nilsson AC; Christensen EB; Stougaard CL; Barnkob MB; Holm DK; Witt AH; Byg KE; Johansen IS; Nielsen C; Sejbaek T
    Front Immunol; 2024; 15():1432348. PubMed ID: 39301017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population.
    Vanamudhu A; Devi Arumugam R; Nancy A; Selvaraj N; Moiden K; Hissar S; Ranganathan UD; Bethunaickan R; Babu S; Kumar NP
    Viruses; 2024 Jul; 16(8):. PubMed ID: 39205152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.
    Picchianti-Diamanti A; Aiello A; Laganà B; Agrati C; Castilletti C; Meschi S; Farroni C; Lapa D; Najafi Fard S; Cuzzi G; Cimini E; Grassi G; Vanini V; Di Rosa R; Salemi S; Nalli G; Salmi A; Repele F; Altera AMG; Maffongelli G; Palazzolo C; Vita S; Leone S; Puro V; Capobianchi MR; Ippolito G; Nicastri E; Goletti D
    Front Immunol; 2021; 12():740249. PubMed ID: 34594343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Ewer KJ; Barrett JR; Belij-Rammerstorfer S; Sharpe H; Makinson R; Morter R; Flaxman A; Wright D; Bellamy D; Bittaye M; Dold C; Provine NM; Aboagye J; Fowler J; Silk SE; Alderson J; Aley PK; Angus B; Berrie E; Bibi S; Cicconi P; Clutterbuck EA; Chelysheva I; Folegatti PM; Fuskova M; Green CM; Jenkin D; Kerridge S; Lawrie A; Minassian AM; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Song R; Snape MD; Tarrant R; Voysey M; Watson MEE; Douglas AD; Hill AVS; Gilbert SC; Pollard AJ; Lambe T;
    Nat Med; 2021 Feb; 27(2):270-278. PubMed ID: 33335323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.